Inactive Instrument

Sterling Biotech Limited

512299

INE324C01038

Sterling Biotech Limited Announces Executive Changes

January 11, 2013 at 02:40 pm IST

Sterling Biotech Limited announced that Ms. Megha R. Chokshi, an assistant company secretary of the company has been designated as compliance officer in place of Mr. Kirtidev J. Khatri.

Latest news about Sterling Biotech Limited

Perfect Day, Inc. completed the acquisition of Sterling Biotech Limited.	30/22/30	CI
Sterling Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2022	12/22/12	CI
Perfect Day, Inc. win a bid to acquire Sterling Biotech Limited for INR 6.38 billion.	18/22/18	CI
Liquidator for Sterling Biotech Invites Fresh Bids to Sell the Company	27/21/27	CI
Sterling Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2020	07/21/07	CI
ACG Capsules Reportedly Seeks NCLT To Reconsider The Bid For Sterling	25/19/25	CI
Sterling Biotech Limited Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2018	11/19/11	CI
Sterling Biotech Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2018	01/19/01	CI
Sterling Biotech Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2018	01/19/01	CI
Sterling Biotech Limited Reports Audited Earnings Results for the Year Ended March 31, 2018	20/18/20	CI
Sterling Biotech Limited Announces Audited Earnings Results for the Year Ended March 31, 2017	06/17/06	CI
Sterling Biotech Limited announced a financing transaction	28/17/28	CI
Sterling Biotech Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2017	12/17/12	CI
Sterling Biotech Limited Announces Audited Earnings Results for the Fourth Quarter and Year Ended March 31, 2017	30/17/30	CI
Sterling Biotech Limited Announces Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016	14/17/14	CI
Sterling Biotech Limited Reports Unaudited Standalone Earnings Results for Three Months and Six Months Ended September 30, 2016	14/16/14	CI
Sterling Biotech Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2016	14/16/14	CI
Sterling Biotech Limited Announces Audited Standalone Earnings Results for the Quarter and Fifteen Months Ended March 31, 2016	31/16/31	CI
Sterling Biotech Limited Reports Unaudited Standalone Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015	12/16/12	CI
Sterling Biotech Limited Announces Change in Financial Year from December to March	01/16/01	CI
Sterling Biotech Limited Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	06/15/06	CI
Sterling Biotech Limited Announces Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	14/15/14	CI
Sterling Biotech Limited Announces Unaudited Standalone Earnings Results for the First Quarter Ended March 31, 2015	15/15/15	CI
Sterling Biotech Limited Appoints Mayuri Patel as Independent Director	17/15/17	CI
Sterling Biotech Ltd Announces Demise of N. B. Patel, Director of the Company	27/15/27	CI

Chart Sterling Biotech Limited

Duration

Period

More charts

Sterling Biotech Limited manufactures gelatine and its derivatives, resinoids, glues, and allopathic pharmaceutical preparations. The Company manufactures Pharma Grade Gelatine and DiCalcium Phosphate, and other Pharma products. The Company manufactures gelatin from animal bones. It offers anticancer products, such as DOXO Rubicin, which is an anti-cancer chemotherapy drug and is classified as an anthracycline antibiotic; IDARUBICIN, which is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug; Daunorubicinis, which is used to treat acute lymphocytic and myelocyticleukemias; IMATINIB, which is a drug used to treat certain cancers, and EPI Rubicin, which is an anthracycline drug used for chemotherapy. Its other products include Lovastatin, which is a cholesterol-lowering agent; DACARBAZINE, which is used to treat Hodgkin disease and malignant melanoma, and Temozolamide, which is an oral alkylating agent used for the treatment of Grade IV astrocytoma.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+40.73%	74TCr
NOVO NORDISK A/S	+32.83%	60TCr
JOHNSON & JOHNSON	-6.30%	35TCr
MERCK & CO., INC.	+15.15%	32TCr
ABBVIE INC.	+4.05%	28TCr
ASTRAZENECA PLC	+15.00%	24TCr
ROCHE HOLDING AG	-5.52%	21TCr
AMGEN INC.	+6.17%	16TCr
PFIZER, INC.	-0.45%	16TCr

Other Pharmaceuticals